Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | Director · SVP, Chief Medical Officer | June 03, 2022 | June 07, 2022 |
| Vor Biopharma Inc.VOR · Entity 4763 | CHIEF MEDICAL OFFICER | February 13, 2025 | February 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date June 03, 2022 · Filed June 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,233 |
Reported balance
After 2022-06-03 transaction · row 1
1 source rowRow 1 · 2022-06-03 · Tax withholding · Disposed 32,667 · Balance 57,233 F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 89,900 restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 172 |
Reported balance
Holding disclosure · report date 2022-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 172 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy adult child | 159 |
Reported balance
Holding disclosure · report date 2022-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 159 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 89,900 restricted stock units.
F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
Vor Biopharma Inc.
Report date February 13, 2025 · Filed February 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,625 |
Reported balance
After 2025-02-13 transaction · row 1
1 source rowRow 1 · 2025-02-13 · Sale · Disposed 2,227 · Balance 126,625 F1: The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2025 Filed Feb 18, 2025 21:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | SaleCommon Stock | 2,227 | $1.42 | $3,162.34 |
DisclosureSEC source: 0001415889-25-004406 · form4-02182025_090225.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,625 F1 · kind: The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:29 UTC | Vor Biopharma Inc. VOR · Entity 4763 | SaleCommon Stock | 2,554 | $1.37 | $3,498.98 |
DisclosureSEC source: 0001415889-25-003734 · form4-02122025_090258.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,852 F1 · kind: The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.33 to $1.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:35 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 1,180 | $1.50 | $1,770.00 |
DisclosureSEC source: 0001415889-25-003364 · form4-02072025_090202.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,406 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 315,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · derivative · entry 9 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires 2035-02-02 F8 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · derivative · entry 8 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-01-28 F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · derivative · entry 7 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2034-01-28 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · derivative · entry 6 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2033-02-05 F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · derivative · entry 5 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,000 shares Expires 2033-02-05 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 364,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · derivative · entry 4 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,000 Underlying: Common Stock · 364,000 shares Expires 2032-10-10 F5 · derivative.exercise_price: The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date. F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: 1/4th of the shares underlying the option vested on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 364,000 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · derivative · entry 3 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 364,000 shares Expires 2032-10-10 F3 · kind: On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the "2015 Plan"), 2021 Equity Incentive Plan (the "2021 Plan") and 2023 Inducement Plan (the "Inducement Plan"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the "Effective Date"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: 1/4th of the shares underlying the option vested on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · nonDerivative · entry 2 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,586 F2 · shares: Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 6, 2025 02:20 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 1,353 | $1.34 | $1,813.02 |
DisclosureSEC source: 0001415889-25-003173 · form4-02062025_020253.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,086 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| December 27, 2024 Filed Dec 31, 2024 21:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | SaleCommon Stock | 10,334 | $1.25 | $12,917.50 |
DisclosureSEC source: 0001415889-24-030316 · form4-12312024_041209.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,439 F1 · kind: The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024. Read SEC document |
| November 06, 2024 Filed Nov 8, 2024 21:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 999 | $0.86 | $859.14 |
DisclosureSEC source: 0001415889-24-026430 · form4-11082024_041107.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,773 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 1,146 | $0.80 | $916.80 |
DisclosureSEC source: 0001415889-24-026127 · form4-11052024_041111.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,772 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:33 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 999 | $0.87 | $869.13 |
DisclosureSEC source: 0001415889-24-020992 · form4-08082024_080858.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,918 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 1,146 | $0.94 | $1,077.24 |
DisclosureSEC source: 0001415889-24-020738 · form4-08052024_040809.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,917 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 22:09 UTC | Vor Biopharma Inc. VOR · Entity 4763 | SaleCommon Stock | 14,645 | $1.39 | $20,356.55 |
DisclosureSEC source: 0001415889-24-015450 · form4-06042024_100605.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,063 F1 · kind: The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.31 to $1.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2024 Filed May 7, 2024 20:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 999 | $1.75 | $1,748.25 |
DisclosureSEC source: 0001415889-24-012460 · form4-05072024_040519.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,708 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 1,146 | $1.77 | $2,028.42 |
DisclosureSEC source: 0001415889-24-012159 · form4-05032024_040525.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,707 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 22:10 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 1,180 | $2.32 | $2,737.60 |
DisclosureSEC source: 0001415889-24-003041 · form4-02082024_100231.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,853 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 00:38 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001415889-24-002104 · form4-02012024_120200.xml · derivative · entry 2 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-01-28 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 00:38 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-002104 · form4-02012024_120200.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,033 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date. Read SEC document |
| November 06, 2023 Filed Nov 8, 2023 21:10 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 999 | $1.82 | $1,818.18 |
DisclosureSEC source: 0001209191-23-054692 · doc4.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,533 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 20:31 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 999 | $2.67 | $2,667.33 |
DisclosureSEC source: 0001209191-23-045181 · doc4.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,532 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| May 08, 2023 Filed May 10, 2023 20:14 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 969 | $4.14 | $4,011.66 |
DisclosureSEC source: 0001209191-23-028458 · doc4.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,531 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs"). Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001209191-23-007787 · doc4.xml · derivative · entry 2 Attar Eyal C. · CIK 0001789076 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2033-02-05 F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:23 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantCommon Stock | 54,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-007787 · doc4.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 20:24 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantEmployee Stock Option (right to buy) · Derivative | 364,000 | $0.00 Strike: $3.77 | $0.00 |
DisclosureSEC source: 0001209191-22-053463 · doc4.xml · derivative · entry 1 Attar Eyal C. · CIK 0001789076 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,000 Underlying: Common Stock · 364,000 shares Expires 2032-10-10 F1 · derivative.exercise_date: 1/4th of the shares underlying the option vest on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date. Read SEC document |
| June 03, 2022 Filed Jun 7, 2022 21:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 32,667 | $0.81 | $26,296.94 |
DisclosureSEC source: 0001104659-22-068995 · tm2217848-1_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Director · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,233 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 89,900 restricted stock units. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 185,900 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001104659-22-033390 · tm229119-2_4seq1.xml · derivative · entry 4 Attar Eyal C. · CIK 0001789076 · Director · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,900 Underlying: Common Stock · 185,900 shares Expires 2032-03-10 F2 · derivative.exercise_date: Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 42,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-033390 · tm229119-2_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · Director · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,900 F1 · shares: These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 14,300 shares on March 10, 2023, (ii) 14,300 shares on March 10, 2024 and (iii) 14,300 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 28, 2022 Filed Mar 1, 2022 22:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 36,000 | $1.73 | $62,280.00 |
DisclosureSEC source: 0001104659-22-028757 · tm227953-1_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.66 to $1.77 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:29 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | SaleCommon Stock | 15,968 | $4.68 | $74,730.24 |
DisclosureSEC source: 0001104659-21-117446 · tm2127534-2_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.85 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 21:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Tax withholdingCommon Stock | 9,032 | $3.98 | $35,947.36 |
DisclosureSEC source: 0001104659-21-110595 · tm2126037-1_4seq1.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,968 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 25,000 restricted stock units Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:12 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 143,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006738 · form4.xml · derivative · entry 5 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,000 Underlying: Common Stock · 143,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:12 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006738 · form4.xml · nonDerivative · entry 2 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 F2 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,000 shares on August 25, 2021, (ii) 25,000 shares on February 25, 2022 and (iii) 25,000 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:12 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-006738 · form4.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · shares: These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 21:01 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 55,000 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001104659-20-038880 · a4.xml · derivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:18 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 77,630 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001140361-19-018074 · form4.xml · derivative · entry 3 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,630 Underlying: Common Stock · 77,630 shares Expires 2029-10-02 F2 · derivative.exercise_date: Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:18 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 200 | $15.00 | $3,000.00 |
DisclosureSEC source: 0001140361-19-018074 · form4.xml · nonDerivative · entry 2 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By child Disclosed balance after: 200 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:18 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 200 | $15.00 | $3,000.00 |
DisclosureSEC source: 0001140361-19-018074 · form4.xml · nonDerivative · entry 1 Attar Eyal C. · CIK 0001789076 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By adult child Disclosed balance after: 200 F1 · balance_after: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.direct: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.